Stockscreener 앱 받기
1.07
5.94%
0.06
전일 마감가:
$1.01
열려 있는:
$1
하루 거래량:
2.10M
Relative Volume:
0.88
시가총액:
$122.65M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.6485
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+2.88%
1개월 성능:
+1.90%
6개월 성능:
-47.03%
1년 성능:
-74.15%
1일 변동 폭
$1.00
$1.12
1주일 범위
$0.9301
$1.20
52주 변동 폭
$0.6611
$5.92
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.07 | 119.19M | 13.45M | -178.23M | -132.53M | -1.65 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Robert W. Baird Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00 - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus
FATE Stock Update: Analyst Lowers Price Target, Maintains Neutra - GuruFocus
4 Analysts Assess Fate Therapeutics: What You Need To Know - Benzinga
Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 R - GuruFocus
Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Resu - GuruFocus
FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Ce - GuruFocus
Fate Therapeutics: Q1 Earnings Snapshot - CT Insider
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
What Is Going On With Fate Therapeutics Inc (NASDAQ: FATE)? - Stocksregister
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by MetLife Investment Management LLC - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN - Defense World
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
Fate Therapeutics Inc (NASDAQ: FATE) Drops -18.14 Percent In Recent Trading, What Questions Do You Have? - Stocksregister
Fate Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages - Defense World
Fate Therapeutics Inc [FATE] Records 50-Day SMA of $1.0480 - knoxdaily.com
LPL Financial LLC Buys New Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Uncovering the Potential of Fate Therapeutics Inc (FATE) Stock - investchronicle.com
There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - Sete News
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - The Manila Times
Fate Therapeutics to Present Clinical and Preclinical Data at ASGCT 28th Annual Meeting - Nasdaq
Was anything negative for Fate Therapeutics Inc (FATE) stock last session? - uspostnews.com
Fate Therapeutics Announces Five Presentations on - GlobeNewswire
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo
Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
FATE Shares Experience Decline in Value - knoxdaily.com
Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fate Therapeutics Inc 주식 (FATE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bressi Jerome Charles | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,980 |
9,269 |
270,203 |
| TAHL CINDY | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,654 |
8,764 |
336,707 |
| Valamehr Bahram | President and CEO |
Jan 10 '25 |
Sale |
1.54 |
8,705 |
13,406 |
349,364 |
1.54%
7.58%
자본화:
|
볼륨(24시간):